Select Page

Migraine Drugs Market is valued around USD 2014.1 Billion in 2019 and expected to reach USD 2971.9 Billion by 2030 with the CAGR of 3.6% over the forecast period.

Migraine Drugs are used for the treatment of neurological condition called as migraine. This condition involves the high intensity headache which can last from hours up to days with several other symptoms such as vomiting, nausea, sensitivity towards light, smell & other. There has been study which proves that female population is more prone to migraine as compared to the males. Migraine is highly manageable disorder with the help of proper medication & slight change in the lifestyle.

Global Migraine Drugs Market report is segmented on the basis of type, administration route, distribution channel and by regional. Based upon type, the migraine drugs market is fragmented into abortive medicine and preventive medicine. On the basis of administration route, the market is categorized into oral, injection and others. Based on distribution channel, the market is fragmented into hospital-based pharmacies, retail pharmacies, and online pharmacies. The regional bifurcation of countries includes North America, Europe, Asia-Pacific, and RoW which are further segmented into major countries such as U.S., UK, France, and others.

The migraine drugs market is mainly driven by the high prevalence rate of migraine along with growing awareness among people which in turn created the demand for migraine drugs. There has been technological advancement with robust product pipeline along with constant product launch. In addition, growing healthcare expenditure as well as FDA approvals to novel therapies for the better management of migraine is also expected to contribute market growth. On the other hand, constant growth in female population accompanied by rising awareness with respect to treatment & prevention of migraine followed by the various organizations aim to further create awareness among large population has anticipated the market growth. However, various side effects associated with the migraine drugs restrain the market growth in near future.

Complete report is available at

The developed regions such as North America and Europe are expected to hold the major market share owing to the presence of major market players in the region followed by technological advancement with rapid use of novel therapies. Asia Pacific is expected to dominate the migraine drugs market in terms of growth rate owing to the high prevalence rate along with huge female population. Moreover, rising healthcare expenditure along with growing awareness among people with regards to the treatment & prevention of migraine are also expected to support the market growth over the forecast period.

The major market players profiled in the migraine drugs market includes Allergan Plc., AstraZeneca, GlaxoSmithKline Plc., Impax Laboratories, Abbott Laboratories, Eisai Co., Ltd., Johnson & Johnson, Merck & Co., Endo International Plc, and Pfizer Inc. among others.